DCGI Approved AstraZeneca’s Lynparza

AstraZeneca India has received a Drugs Controller General of India (DCGI) approval to market Lynparza (olaparib) as a monotherapy for the adjuvant treatment of adult patients with BRCA-mutated HER2-negative high-risk early breast cancer.